Information:
Error:
Keywords
HIV ×
- Clinical Trial (103)
- Hypersensitivity (32)
- HIV Infections (26)
- Clinical Trial, Phase III (25)
- Pneumococcal Vaccines (25)
- Anus Neoplasms (18)
- Eligibility Determination (16)
- Laboratories (12)
- Adverse event (11)
- Sarcoma, Kaposi (10)
- Vaccination (10)
- Drug Therapy (8)
- On-Study Form (7)
- Lymphoma, Non-Hodgkin (7)
- Papillomavirus Vaccines (6)
- Death (5)
- Follow-Up Studies (5)
- Physical Examination (4)
- Serology (4)
- Burkitt Lymphoma (4)
- Informed Consent (4)
- Patch Tests (4)
- Rotavirus (3)
- Clinical Laboratory Services (3)
- Concomitant Medication (3)
- End of Study (3)
- Demography (3)
- Pathology (3)
- Pediatrics (3)
- Pregnancy Tests (2)
- HIV-1 (2)
- Substance Abuse Detection (2)
- Lymphoma, B-Cell (2)
- Urinalysis (2)
- Sirolimus (2)
- Healthy Volunteers (2)
- Registration (2)
- Common Data Elements (CDE) (2)
- Off-Treatment (2)
- Trial screening (2)
- Disease Response (2)
- Communicable Diseases (2)
- Alcohol Drinking (2)
- Hepatitis B (2)
- Hepatitis C (2)
- Medical History Taking (2)
- Microbiology (2)
- Poliovirus Vaccine, Oral (1)
- Postnatal Care (1)
- Pregnancy (1)
- Prenatal Care (1)
- Prostatic Hyperplasia (1)
- Psychiatry (1)
- Random Allocation (1)
- Reference Values (1)
- Registries (1)
- Rhinitis, Allergic, Perennial (1)
- Schizophrenia (1)
- Sleep Disorders (1)
- Spinal Puncture (1)
- Streptococcus pneumoniae (1)
- BCG Vaccine (1)
- Cohort Studies (1)
- Lymphoma, Large B-Cell, Diffuse (1)
- Central Nervous System Neoplasms (1)
- Hepatitis B Vaccines (1)
- Clinical Trial, Phase I (1)
- Viral Load (1)
- Brain Neoplasms (1)
- Clinical Chemistry Tests (1)
- Pulmonary Disease, Chronic Obstructive (1)
- Consent Forms (1)
- Delivery, Obstetric (1)
- Follicle Stimulating Hormone, Human (1)
- Infectious Disease Medicine (1)
- Child (1)
- Post-Exposure Prophylaxis (1)
- Symptom Assessment (1)
- Tobacco Use (1)
- Perinatal Death (1)
- Baseline (1)
- Treatment Form (1)
- Specimen (1)
- Draft Standard (1)
- Released Standard (1)
- COVID-19 (1)
- Cotinine (1)
- Disease (1)
- Estradiol (1)
- Genetic Testing (1)
- Glucocorticoids (1)
- Haemophilus influenzae (1)
- Hemophilia A (1)
- Infant (1)
- Infection (1)
- Lymph Nodes (1)
- Measles Vaccine (1)
- Meningitis (1)
- Neurology (1)
Table of contents
Selected data models
You must log in to select data models for download or further analysis.
138 Search results.
Itemgroup: pht002504
Eligibility
1 itemgroup 1 itempht002505.v1.p1
1 itemgroup 3 itemspht002506.v1.p1
1 itemgroup 3 items Itemgroups: Administrative documentation,Clinical HIV staging,HIV infection WHO clinical stage 1,HIV infection WHO clinical stage 2,HIV infection WHO clinical stage 3,HIV infection WHO clinical stage 4
Itemgroups: Inclusion Criteria,Exclusion Criteria
Itemgroups: Inclusion Criteria,Exclusion Criteria
Itemgroups: Inclusion Criteria,Exclusion Criteria
Itemgroups: Header Module,HIV History,Does the participant have a history of high grade dysplasia,Prior Therapy
Itemgroup: Specimen
Itemgroups: HIV transmission risk,Current antiretroviral therapy,Antiretroviral therapy duration before SARS-CoV-2 detection,Antiretroviral therapy changed / started during SARS-Cov-2 infection,Antiretroviral therapy regimen at end of follow-up period,CD4+ T-cell count (abs.),CD4+ T-cell count (rel.),HIV CDC stage at baseline,CD8+ T-cell count (abs.),CD8+ T-cell count (rel.),HIV viral load,Opportunistic infections, AIDS-defining illnesses, STI during COVID-19,Is data entry for this section finished?
Itemgroups: Concomitant Medications,Comments
Itemgroups: Inclusion Criteria,Exclusion Criteria
Itemgroups: Medical Conditions,Alcohol Intake,Drug and Alcohol Sreen,Serology - HIV Screen,Electronically Transferred Laboratory Data
Itemgroups: Administrative documentation,Section 1: General SAE information,Section 2: Seriousness,Section 3: Demography Data,Section 4: SAE recurrence,Section 5: Possible Causes of SAE Other Than Investigational Product(s),Section 6: Relevant Medical Conditions,Section 7: Other Relevant Risk Factors,Section 8: Relevant Concomitant Medications,Section 9: Details of investigational product(s),Section 10: Details of Relevant Assessments,Section 11: Narrative Remarks,Section 12: SAE additional / follow-up information,Investigator's signature